Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Operating Leases: 2019-2024

Historic Operating Leases for Ocular Therapeutix (OCUL) over the last 6 years, with Dec 2024 value amounting to $5.3 million.

  • Ocular Therapeutix's Operating Leases fell 35.10% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 35.10%. This contributed to the annual value of $5.3 million for FY2024, which is 22.29% down from last year.
  • As of FY2024, Ocular Therapeutix's Operating Leases stood at $5.3 million, which was down 22.29% from $6.9 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Operating Leases peaked at $8.7 million during FY2022, and registered a low of $5.3 million during FY2024.
  • Its 3-year average for Operating Leases is $7.0 million, with a median of $6.9 million in 2023.
  • As far as peak fluctuations go, Ocular Therapeutix's Operating Leases spiked by 46.49% in 2022, and later decreased by 22.29% in 2024.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Operating Leases stood at $7.5 million in 2020, then dropped by 21.52% to $5.9 million in 2021, then surged by 46.49% to $8.7 million in 2022, then dropped by 20.74% to $6.9 million in 2023, then dropped by 22.29% to $5.3 million in 2024.